Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Cologne
Rituximab and low-dose total-nodal irradiation both have shown promising activity in patients with NHL. Moreover, the radiolabelled antibody Zevalin has been approved for the treatment of relapsed NHL. The patients in this study have a poor prognosis. The treatment strategy aims to control the disease and to ameliorate disease related symptoms with minimal toxicity. Both, rituximab and low-dose radiotherapy are associated with minor toxicity if applied alone.
The primary objective of the study is therefore to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkin's lymphoma.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
B-cell non-Hodgkin's lymphoma
At least one prior antitumor therapy
ECOG performance status 0-2
No major organ dysfunction
Written informed consent
You may not be if
The following histologies are excluded: Burkitt's lymphoma, mantle-cell lymphoma, primary CNS-lymphoma, HIV-associated lymphoma